Acumen Pharmaceuticals Inc.

06/05/2025 | Press release | Distributed by Public on 06/05/2025 14:37

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 4, 2025, Acumen Pharmaceuticals, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2025. Of the 60,573,425 shares outstanding as of the record date, 51,524,049 shares, or approximately 85]%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1: The stockholders elected three nominees to serve as Class I directors until the 2028 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:
Name Votes For Votes Withheld Broker Non-Votes
Kimberlee C. Drapkin 30,008,667 4,022,275 17,493,107
Jeffrey Ives, Ph.D. 30,040,637 3,990,305 17,493,107
Sean Stalfort 29,923,560 4,107,382 17,493,107
Proposal No. 2:The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes were cast as follows:
Votes For
Votes Against
Abstained
Ratification of appointment of Ernst & Young LLP
51,369,800 118,735 35,514
Acumen Pharmaceuticals Inc. published this content on June 05, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 05, 2025 at 20:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io